Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody-Drug Conjugates.

Gébleux R, Briendl M, Grawunder U, Beerli RR.

Methods Mol Biol. 2019;2012:1-13. doi: 10.1007/978-1-4939-9546-2_1.

PMID:
31161500
2.

Characterization of the housekeeping sortase from the human pathogen Propionibacterium acnes: first investigation of a class F sortase.

Di Girolamo S, Puorger C, Castiglione M, Vogel M, Gébleux R, Briendl M, Hell T, Beerli RR, Grawunder U, Lipps G.

Biochem J. 2019 Feb 19;476(4):665-682. doi: 10.1042/BCJ20180885.

PMID:
30670573
3.

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

D'Amico L, Menzel U, Prummer M, Müller P, Buchi M, Kashyap A, Haessler U, Yermanos A, Gébleux R, Briendl M, Hell T, Wolter FI, Beerli RR, Truxova I, Radek Š, Vlajnic T, Grawunder U, Reddy S, Zippelius A.

J Immunother Cancer. 2019 Jan 21;7(1):16. doi: 10.1186/s40425-018-0464-1.

4.

Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.

Hellmann I, Waldmeier L, Bannwarth-Escher MC, Maslova K, Wolter FI, Grawunder U, Beerli RR.

Front Immunol. 2018 Nov 2;9:2490. doi: 10.3389/fimmu.2018.02490. eCollection 2018.

5.

Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, Martinez GJ, Fallahi M, Soden J, Freeth J, Beerli RR, Grawunder U, Hudecek M, Rader C.

J Mol Biol. 2017 Sep 15;429(19):2954-2973. doi: 10.1016/j.jmb.2017.08.003. Epub 2017 Aug 14.

6.

Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.

Klose D, Woitok M, Niesen J, Beerli RR, Grawunder U, Fischer R, Barth S, Fendel R, Nachreiner T.

PLoS One. 2017 Jul 13;12(7):e0180305. doi: 10.1371/journal.pone.0180305. eCollection 2017.

7.

Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.

Stefan N, Gébleux R, Waldmeier L, Hell T, Escher M, Wolter FI, Grawunder U, Beerli RR.

Mol Cancer Ther. 2017 May;16(5):879-892. doi: 10.1158/1535-7163.MCT-16-0688. Epub 2017 Mar 3.

8.

Cystatin F is a biomarker of prion pathogenesis in mice.

Nuvolone M, Schmid N, Miele G, Sorce S, Moos R, Schori C, Beerli RR, Bauer M, Saudan P, Dietmeier K, Lachmann I, Linnebank M, Martin R, Kallweit U, Kana V, Rushing EJ, Budka H, Aguzzi A.

PLoS One. 2017 Feb 8;12(2):e0171923. doi: 10.1371/journal.pone.0171923. eCollection 2017.

9.

Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries.

Waldmeier L, Hellmann I, Gutknecht CK, Wolter FI, Cook SC, Reddy ST, Grawunder U, Beerli RR.

MAbs. 2016 May-Jun;8(4):726-40. doi: 10.1080/19420862.2016.1160990. Epub 2016 Mar 17.

10.

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.

Beerli RR, Hell T, Merkel AS, Grawunder U.

PLoS One. 2015 Jul 1;10(7):e0131177. doi: 10.1371/journal.pone.0131177. eCollection 2015.

11.

Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.

Beerli RR, Bauer M, Fritzer A, Rosen LB, Buser RB, Hanner M, Maudrich M, Nebenfuehr M, Toepfer JA, Mangold S, Bauer A, Holland SM, Browne SK, Meinke A.

MAbs. 2014;6(6):1608-20. doi: 10.4161/mabs.36292.

12.

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.

Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF.

Allergy. 2014 Mar;69(3):338-47. doi: 10.1111/all.12327. Epub 2013 Dec 19. Erratum in: Allergy. 2014 Aug;69(8):1118.

PMID:
24354793
13.

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.

14.

Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody.

Tars K, Kotelovica S, Lipowsky G, Bauer M, Beerli RR, Bachmann MF, Maurer P.

J Mol Biol. 2012 Jan 6;415(1):118-27. doi: 10.1016/j.jmb.2011.10.042. Epub 2011 Nov 3.

PMID:
22079050
15.

Mechanisms of allergen-specific desensitization.

Uermösi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB, Kündig TM, Saudan P, Bachmann MF.

J Allergy Clin Immunol. 2010 Aug;126(2):375-83. doi: 10.1016/j.jaci.2010.05.040. Epub 2010 Jul 10.

PMID:
20624641
16.

Mining human antibody repertoires.

Beerli RR, Rader C.

MAbs. 2010 Jul-Aug;2(4):365-78. Epub 2010 Jul 1. Review.

17.

Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.

Beerli RR, Bauer M, Schmitz N, Buser RB, Gwerder M, Muntwiler S, Renner WA, Saudan P, Bachmann MF.

Virol J. 2009 Dec 21;6:224. doi: 10.1186/1743-422X-6-224.

18.

Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells.

von Allmen CE, Schmitz N, Bauer M, Hinton HJ, Kurrer MO, Buser RB, Gwerder M, Muntwiler S, Sparwasser T, Beerli RR, Bachmann MF.

Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11673-8. doi: 10.1073/pnas.0812569106. Epub 2009 Jun 29.

19.

Isolation of human monoclonal antibodies by mammalian cell display.

Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, Saudan P, Bachmann MF.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14336-41. doi: 10.1073/pnas.0805942105.

20.

Identification of Ly-6K as a novel marker for mouse plasma cells.

von Allmen CE, Bauer M, Dietmeier K, Buser RB, Gwerder M, Muntwiler S, Utzinger S, Saudan P, Bachmann MF, Beerli RR.

Mol Immunol. 2008 May;45(10):2727-33. doi: 10.1016/j.molimm.2008.02.009. Epub 2008 Mar 26.

PMID:
18372042
21.

VSIG4, a B7 family-related protein, is a negative regulator of T cell activation.

Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, Gatto D, Sebbel P, Beerli RR, Sonderegger I, Kopf M, Saudan P, Bachmann MF.

J Clin Invest. 2006 Oct;116(10):2817-26.

22.

Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation.

Bachmann MF, Beerli RR, Agnellini P, Wolint P, Schwarz K, Oxenius A.

Eur J Immunol. 2006 Apr;36(4):842-54.

23.

CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells.

Marsland BJ, Bättig P, Bauer M, Ruedl C, Lässing U, Beerli RR, Dietmeier K, Ivanova L, Pfister T, Vogt L, Nakano H, Nembrini C, Saudan P, Kopf M, Bachmann MF.

Immunity. 2005 Apr;22(4):493-505.

24.

Rapid functional cloning of cell adhesion molecules.

Ruedl C, Bauer M, Beerli RR, Lässing U, Dietmeier K, Ivanova L, Vogt L, Saudan P, Bachmann MF.

Biotechniques. 2004 Dec;37(6):912, 914, 916. No abstract available.

25.

The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3.

Sirena D, Lilienfeld B, Eisenhut M, Kälin S, Boucke K, Beerli RR, Vogt L, Ruedl C, Bachmann MF, Greber UF, Hemmi S.

J Virol. 2004 May;78(9):4454-62.

26.

Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.

Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF 3rd.

J Biol Chem. 2003 Nov 28;278(48):47812-9. Epub 2003 Aug 28.

27.

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE.

Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8. Epub 2003 Jul 9.

28.

Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor.

Hyland S, Beerli RR, Barbas CF, Hynes NE, Wels W.

Oncogene. 2003 Mar 13;22(10):1557-67.

PMID:
12629519
29.

Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins.

Segal DJ, Beerli RR, Blancafort P, Dreier B, Effertz K, Huber A, Koksch B, Lund CV, Magnenat L, Valente D, Barbas CF 3rd.

Biochemistry. 2003 Feb 25;42(7):2137-48.

PMID:
12590603
30.

Engineering polydactyl zinc-finger transcription factors.

Beerli RR, Barbas CF 3rd.

Nat Biotechnol. 2002 Feb;20(2):135-41. Review.

PMID:
11821858
31.

Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors.

Dreier B, Beerli RR, Segal DJ, Flippin JD, Barbas CF 3rd.

J Biol Chem. 2001 Aug 3;276(31):29466-78. Epub 2001 May 4.

32.

Chemically regulated zinc finger transcription factors.

Beerli RR, Schopfer U, Dreier B, Barbas CF 3rd.

J Biol Chem. 2000 Oct 20;275(42):32617-27.

33.

Positive and negative regulation of endogenous genes by designed transcription factors.

Beerli RR, Dreier B, Barbas CF 3rd.

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1495-500.

34.
36.

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE.

Mol Cell Biol. 1998 Sep;18(9):5042-51.

37.

Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.

Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE.

Cancer Res. 1997 Sep 1;57(17):3804-11.

38.
39.

Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.

Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE.

Oncogene. 1996 Jul 18;13(2):275-82.

PMID:
8710366
40.

Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.

Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K.

Oncogene. 1996 Jun 20;12(12):2535-47.

PMID:
8700512
42.

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y.

EMBO J. 1996 Jan 15;15(2):254-64.

43.

Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies.

Beerli RR, Wels W, Hynes NE.

Breast Cancer Res Treat. 1996;38(1):11-7. Review.

PMID:
8825118
44.

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE.

Mol Cell Biol. 1995 Dec;15(12):6496-505.

46.

Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody.

Beerli RR, Wels W, Hynes NE.

Biochem Biophys Res Commun. 1994 Oct 28;204(2):666-72.

PMID:
7980527
47.

Intracellular expression of single chain antibodies reverts ErbB-2 transformation.

Beerli RR, Wels W, Hynes NE.

J Biol Chem. 1994 Sep 30;269(39):23931-6.

Supplemental Content

Loading ...
Support Center